Market Overview

UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Related MRK
Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

In a report released Monday, JP Morgan analyst David Risinger upgraded Merck (NYSE: MRK) from Underweight to Overweight with a price target of $60.

Risinger notes, "Mgmt is taking the right steps—cost cuts, R&D changes, and considering strategic action—to boost company's outlook." One of the driving catalysts that the report mentioned is MK-3475, an immuno-oncology candidate which Merck filed for approval a year earlier than expected.

MRK closed Friday at $51.98 and is currently up nearly 3% at the $53.37 level.

Posted-In: News Upgrades Price Target Markets Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional